MASS CYTOMETRY REVEALED LEUKEMIC MICROENVIRONMENT COMPLEXITY: IMPLICATIONS FOR IMMUNOTHERAPY IN A MOUSE MODEL OF CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Marina Wierz, 214640
FIRST-IN-CLASS ORAL TYROSINE KINASE INHIBITOR (KAN0439834) TARGETING ROR1 INDUCED SIGNIFICANT APOPTOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS
EHA Learning Center, Mohammad Hojjat-Farsangi, 214641
IDENTIFICATION OF A MIR-146B-FASL AXIS IN THE DEVELOPMENT OF NEUTROPENIA IN T-LARGE GRANULAR LYMPHOCYTES LEUKEMIA
EHA Learning Center, Giulia Calabretto, 214656
REFINED DETECTION AND PHASING OF STRUCTURAL ABERRATIONS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA WITH LINKED-READ WHOLE GENOME SEQUENCING
EHA Learning Center, Yanara Marincevic-Zuniga, 215240
AMPLICON-BASED NGS AS A TOOL FOR THE IDENTIFICATION OF NEW MARKERS WITH POOR PROGNOSIS IN B-ALL
EHA Learning Center, Adrián Montaño, 215241
EXTRAMEDULLARY LATE RELAPSES IN ATYPICAL SITES OF ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE STUDY OF THE ITALIAN ASSOCIATION OF PEDIATRIC HEMATOLOGY AND ONCOLOGY (AIEOP)
EHA Learning Center, Giovanna Giagnuolo, 215257
INCIDENCE AND OUTCOME OF RELAPSES IN YOUNG ADULTS (18-60 YR) WITH PH--POSITIVE ALLTREATED WITH IMATINIB, CHEMOTHERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (PETHEMA ALLPH08 TRIAL)
EHA Learning Center, Josep-Maria Ribera, 215258
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA USING MULTIPARAMETRIC FLOW CYTOMETRY IS HIGHLY PREDICTIVE OF OUTCOME
EHA Learning Center, Chinmayee Kakirde, 215274
EXPRESSION OF CD25 FLUCTUATES IN THE LEUKEMIC STEM CELL POPULATION OF CD25-POSITIVE AML
EHA Learning Center, Yuki Kageyama, 215275
NEO2734, A NOVEL HIGHLY POTENT ORAL DUAL BET AND P300/CBP BROMODOMAIN INHIBITOR FOR TREATMENT OF HEMATOLGICAL MALIGNANCIES
EHA Learning Center, Bill Brown, 215291
ACUTE MYELOID LEUKEMIA INDUCED TRANSFORMATION OF THE HUMAN BONE MARROW MICROENVIRONMENT PREDICTS CLINICAL OUTCOME
EHA Learning Center, Yiyang Chen, 215292
CYTOGENETIC AND MOLECULAR DRIVERS OF OUTCOME WITH VENETOCLAX-BASED COMBINATION THERAPIES IN TREATMENT-NAÏVE ELDERLY PATIENTS WITH AML
EHA Learning Center, Stephen Strickland, 215307
RANDOMIZED OPEN-LABEL, PHASE III MULTICENTER TRIAL TO EVALUATE AZACITIDINE POST-REMISSION THERAPY IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA
EHA Learning Center, Esther OLIVA, 215308
CLADRIBINE ADDED TO STANDARD INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKAEMIA, 4-YEAR EXPERIENCES FROM SLOVENIA
EHA Learning Center, Saša Anžej Doma, 215323
DECITABINE AS SINGLE AGENT FOR TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS: A RETROSPECTIVE, MULTICENTER REAL LIFE STUDY OF THE “RETE EMATOLOGICA PUGLIESE” (REP)
EHA Learning Center, Maria Pia Loglisci, 215324
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE PHASE 1B ACE-LY-002 STUDY
EHA Learning Center, Martin J. S. Dyer, 215339
OUTCOME OF PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)
EHA Learning Center, Robert Pytlik, 215340
ARE OUTCOMES IMPROVING IN POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER? A RETROSPECTIVE ANALYSIS OF THE LAST 10 YEARS
EHA Learning Center, Nicholas Denny, 215355
PHASE II STUDY WITH OBINUTUZUMAB-DHAP IN RELAPSED/REFRACTORY DLBCL PATIENTS BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION: A STUDY FROM THE FONDAZIONE ITALIANA LINFOMI (GIOTTO STUDY)
EHA Learning Center, Luigi Rigacci, 215356
EFFECT OF THROMBOELASTOGRAPHY DEFINED COAGULOPATHY IN TRAUMATIC BRAIN INJURY
EHA Learning Center, DIBYENDU DE, 215371
ASSESSMENT AT DIAGNOSIS OF 200 PATIENTS WITH A PNH CLONE OR GPI-DEFICIENT CELLS ≥0.01% ENROLLED IN A NATION-WIDE MULTICENTRIC PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Orianne Wagner-Ballon, 215372
DYNAMIC OF TELOMERIC PARAMETERS IN RELAPSING OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AN ANALYSIS OF THE FILO ICLL001 BOMP TRIAL
EHA Learning Center, laura bounaix, 215387
HIGH CD9 EXPRESSION IS ASSOCIATED WITH THE MYD88 L265P MUTATION AND REDUCED FAILURE-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Jennifer Brown, 215388
COMPARISON OF CELLULAR AND CELL-FREE DNA FOR THE DETECTION AND MONITORING OF BTK MUTATED CLL CLONES IN PATIENTS WITH SUBSEQUENT THERAPY AFTER IBRUTINIB FAILURE
EHA Learning Center, Wiebke Schier, 215404
NOVEL STRATEGIES OF TARGETING P53 RELATED VULNERABILITIES IN T-PLL CELLS
EHA Learning Center, Jana von Jan, 215405
FLOW CYTOMETRY AND PCR-BASED T-CELL CLONALITY TESTING FOR DISCRIMINATING BETWEEN REACTIVE AND NEOPLASTIC PROLIFERATION OF LARGE GRANULAR LYMPHOCYTES
EHA Learning Center, Natalia Chernova, 215420
A US BASED SURVEY: THE EXPERIENCES AND PERSPECTIVES OF 1147 CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS
EHA Learning Center, Brian Koffman, 215421
PONATINIB 15 MG DAILY, COMBINING EFFICACY AND TOLERABILITY. A RETROSPECTIVE SURVEY IN ITALY.
EHA Learning Center, Gianni Binotto, 215436
THE EUTOS LONG-TERM SURVIVAL SCORE PREDICTS RESPONSE AND SURVIVAL OF ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS BETTER THAN SOKAL SCORE
EHA Learning Center, Fausto Castagnetti, 215437
COMBINATION TREATMENT OF RITUXIMAB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR WARM AUTOIMMUNE HEMOLYTIC ANEMIA
EHA Learning Center, Caroline Piatek, 215452
THE ESTABLISHMENT OF SD RAT MODEL AND HISTOPATHOLOGICAL STUDY OF IMMUNE HEMOLYTIC DISEASE INDUCED BY ANTIBODY.
EHA Learning Center, sai yan, 215453
ALPS AND GAUCHER DISEASE. A CLINICAL AND IMMUNOLOGICAL OVERLAP
EHA Learning Center, Maurizio Miano, 215454
ALLOGENEIC NK CELLS AND THEIR USE IN CLINICAL TRIALS
EHA Learning Center, Ludovit Bielik, 215468
IMMUNO-T, A MOTION COMIC EDUCATING PATIENTS AND CAREGIVERS ON HOW IMMUNOTHERAPY WORKS.
EHA Learning Center, Tessa Kerre, 215469
PERTURBATION OF FETAL LIVER STROMAL CELL FUNCTION BY TRISOMY 21 PROMOTES INCREASED ERYTHRO-MEGAKARYOPOIESIS BY FETAL HSPC
EHA Learning Center, Natalina Elliott, 215470
NIVOLUMAB RESTORES SENSITIVITY TO CHEMOTHERAPY IN CHEMOREFRACTORY CLASSICAL HODGKIN LYMPHOMA PATIENTS
EHA Learning Center, Carmelo Carlo-Stella, 215484
EARLY DETECTION OF RECURRENCE IN HIGH-RISK HODGKIN LYMPHOMA IN FIRST COMPLETE REMISSION IMPROVES OUTCOME
EHA Learning Center, Novella Pugliese, 215485
THE RISK OF LUNG CANCER IN HODGKIN LYMPHOMA SURVIVORS; A US POPULATION-BASED STUDY.
EHA Learning Center, Mohamed Moussa, 215486
CD5-NEGATIVE MANTLE CELL LYMPHOMA: A DIAGNOSTIC CHALLENGE IN LEUKEMIC NON-NODAL CASES EXCLUSIVELY DIAGNOSED IN PERIPHERAL BLOOD
EHA Learning Center, Sara Montesdeoca Romero, 215500
MARGINAL-ZONE LYMPHOMA WITH AND WITHOUT ASSOCIATION OF HEPATITIS C VIRUS INFECTION: CLINICAL CORRELATION AND TREATMENT RESULTS
EHA Learning Center, Gayane Tumyan, 215501
STUDY OF THE DISSEMINATION PATTERNS AND CLONAL RELATIONSHIP IN DIFFERENT SITES IN MULTI-SITED MALT LYMPHOMAS. A SINGLE CENTRE ANALYSIS.
EHA Learning Center, Maria Condom, 215502
CHARACTERISTICS OF HEMATOLOGICAL PATIENTS WITH BLOOD CULTURES PROVEN SEPSIS – EXPERIENCE OF ONE CENTER
EHA Learning Center, Karla Jakobac, 215518
CHARACTERISTICS AND OUTCOME OF POLYMICROBIAL BLOODSTREAM INFECTIONS (P-BSI) IN PATIENTS WITH HEMATOLOGICAL CANCER.
EHA Learning Center, Maria Elena Zannier, 215519
IS ANTIMICROBIAL PROPHYLAXIS NECESSARY FOR LYMPHOMA PATIENTS? A SINGLE CENTRE, REAL-LIFE EXPERIENCE
EHA Learning Center, Abdulkerim Yıldız, 215520
GROWING IMPORTANCE OF FLOW CYTOMETRY (FCM) IN THE DIAGNOSTICS OF MYELODYSPLASTIC SYNDROMES: SENSITIVITY AND SPECIFICITY OF THE UP-TO-DATE SCORING SYSTEMS UNDER SPECIAL CONSIDERATION OF THE NEW IFSCORE
EHA Learning Center, Uta OELSCHLAEGEL, 215534
EXPLORING THE LONG NON-CODING RNA TRANSCRIPTOME IN JUVENILE MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Mattias Hofmans, 215535
A MIR-150 / TET3 PATHWAY REGULATES THE GENERATION OF MOUSE AND HUMAN NON-CLASSICAL MONOCYTE SUBSET
EHA Learning Center, Dorothée Selimoglu-Buet, 215536
HYPOMETHYLATING AGENTS ASSOCIATED INFECTIONS - SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
EHA Learning Center, Liat shargian-alon, 215550
RESPONSE TO HYPOMETHYLATING AGENTS IMPROVES LONG-TERM OUTCOMES FOR LOWER-RISK PATIENTS WITH MYELODYSPLASTIC SYNDROME IN CASE-MATCHED COHORTS
EHA Learning Center, Dongwon Baek, 215551
A SYSTEMATIC REVIEW PROVIDES LIMITED CLINICAL EVIDENCE FOR ADDITIONAL EFFICACY OF G-CSF + ESA COMPARED TO FULL-DOSE ESA ALONE IN THE TREATMENT OF ANEMIA IN PATIENTS WITH LOW-RISK MDS
EHA Learning Center, Lucas Affentranger, 215552
SYSTEMATIC IDENTIFICATION OF PHARMACOGENOMICS INTERACTIONS MODULATING DRUG RESPONSES IN MULTIPLE MYELOMA
EHA Learning Center, Muntasir Majumder, 215567
ADAR1-MEDIATED-NEIL1 EDITING IS OF BIOLOGICAL SIGNIFICANCE IN MULTIPLE MYELOMA
EHA Learning Center, Phaik Ju Teoh, 215568
IRON INCREASES THE EFFICACY OF STANDARD MULTIPLE MYELOMA THERAPY IN TRANSGENIC VK*MYC MODEL
EHA Learning Center, Jessica Bordini, 215569
TARGETED LIPOSOMAL MULTI-DRUG DELIVERY TO TUMOR-ASSOCIATED ENDOTHELIUM AS A NOVEL STRATEGY TO REVERSE MICROENVIRONMENT-INDUCED DRUG RESISTANCE IN MULTIPLE MYELOMA
EHA Learning Center, Cinzia Federico, 215583
WNT/Β-CATENIN AND HEDGEHOG INHIBITORS AS THERAPEUTIC APPROACHES IN B-CELL NEOPLASMS
EHA Learning Center, Ana Bela Sarmento Ribeiro, 215584
MULTIPLE MYELOMA INDUCES CHANGES IN BONE MARROW ADIPOCYTES IN VITRO AND IN VIVO
EHA Learning Center, Michaela Reagan, 215585
LENALIDOMIDE-PREDNISONE VS LENALIDOMIDE ALONE MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INDIVIDUAL PATIENT DATA META-ANALYSIS OF 2 RANDOMIZED PHASE III TRIALS.
EHA Learning Center, Francesca Gay, 215599
A GLOBAL TREATMENT STANDARD IN MULTIPLE MYELOMA (MM) REMAINS ELUSIVE DESPITE ADVANCES IN CARE OVER 15 YEARS: FIRST RESULTS FROM INSIGHT MM, THE LARGEST GLOBAL PROSPECTIVE, OBSERVATIONAL MM STUDY
EHA Learning Center, Mario Boccadoro, 215600
TREATMENT AND SURVIVAL OF PATIENTS WITH PRIMARY PLASMA CELL LEUKEMIA: A NATIONWIDE POPULATION-BASED STUDY AMONG 179 PATIENTS DIAGNOSED IN THE NETHERLANDS FROM 1989 TO 2015
EHA Learning Center, Avinash Dinmohamed, 215601
TREATMENT OF IGM-ASSOCIATED SYSTEMIC AL AMYLOIDOSIS WITH RITUXIMAB-BENDAMUSTINE
EHA Learning Center, Richa Manwani, 215615
TANDEM TRANSPLANTATION OVERCOMES POOR PROGNOSIS IN NEWLY DIAGNOSED EXTRAMEDULLARY MYELOMA WITH HIGH-RISK CYTOGENETICS: A RETROSPECTIVE STUDY BY THE CMWP-EBMT
EHA Learning Center, Nico Gagelmann, 215616
VENETOCLAX MONOTHERAPY AND COMBINED WITH DEXAMETHASONE AS TARGETED THERAPY FOR RELAPSED/REFRACTORY T(11;14) MULTIPLE MYELOMA
EHA Learning Center, Jonathan Kaufman, 215617
AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN AL AMYLOIDOSIS: SURVIVAL IMPROVEMENT IN DIFFERENT RISK CATEGORIES IN A SINGLE CENTER EXPERIENCE

EHA Learning Center, Angelo Belotti, 215631
COMPARABLE OUTCOMES USING PROPYLENE GLYCOL-FREE MELPHALAN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
EHA Learning Center, Kevin Miller, 215632
ACTIVITY AND SAFETY OF DARATUMUMAB MONOTHERAY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA REQUIRING DIALYSIS: PRELIMINARY RESULTS OF A SPANISH, RETROSPECTIVE, MULTICENTER TRIAL
EHA Learning Center, Maria Jose cejalvo, 215633
NLR AS SURROGATE OF MYELOID IMMUNE SUPPRESSION CAN PREDICT EARLY SPLENIC RESPONSE TO RUXOLITINIB IN MYELOFIBROSIS
EHA Learning Center, Alfio Bonanno, 215647
POSSIBLE SOMATIC MOSAICISM OF THE JAK2 GENE IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Naoki Mori, 215648
MULTICENTER SURVEY ON MANAGEMENT AND OUTCOME OF A RARE HEMATOLOGIC DISEASE: ADULT ONSET HISTIOCYTOSES.
EHA Learning Center, Davide Lazzarotto, 215649
MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY
EHA Learning Center, Caroline Mcnamara, 215663
JAK2 ALLELIC RATIO PREDICT HIGHER TROMBOTIC RISK IN MYELOFIBROSIS PATIENTS. A SINGLE CENTER EXPERIENCE ON 143 PATIENTS.
EHA Learning Center, Mirko Farina, 215664
RUXOLITINIB AND HYDROXYUREA COMBINATION FOR THE TREATMENT OF MYELOFIBROSIS
EHA Learning Center, Novella Pugliese, 215665
DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2
EHA Learning Center, Junya Kuroda, 215680
INTEGRATIVE GENOME-WIDE ANALYSIS REVEALS REGULATION OF CELL PROLIFERATION INVOLVING MULTIPLE SIGNALING PATHWAYS BY BRD4-BINDING TARGET GENES IN MANTLE CELL LYMPHOMA CELL LINES.
EHA Learning Center, Taku Tsukamoto, 215681
TRANSCRIPTOME SEQUENCING IN DIFFUSE LARGE B-CELL LYMPHOMA - RIBOSOME BIOGENESIS AND DYSREGULATION OF THE ACTIN CYTOSKELETON ARE ASSOCIATED WITH IMMUNOCHEMOTHERAPY RESISTANCE
EHA Learning Center, Mimmie Stern, 215682
RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B
EHA Learning Center, Wan-Yi Zhai, 215697
A HIGH-THROUGHPUT SCREENING ASSAY TO EVALUATE CHEMOTHERAPY-INDUCED MYELOSUPPRESSION USING HEALTHY PERIPHERAL BLOOD AND BONE MARROW
EHA Learning Center, Dimitrios Tsallos, 215698
A NOVEL ACQUIRED RUNX1 VARIANT IS RESPONSIBLE FOR ANKRD26 DYSREGULATION AND THROMBOCYTOPENIA IN SPORADIC FORM OF MYELODYSPLASTIC SYNDROME
EHA Learning Center, Fabrizio vianello, 215699
OCCURRENCE AND MANAGEMENT OF HEPATOBILIARY ADVERSE EVENTS (AES) IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING LONG-TERM TREATMENT WITH ELTROMBOPAG: RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Abderrahim Khelif, 215714
BENEFIT OF EARLY TREATMENT WITH BLINATUMOMAB: LONG-TERM SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING FIRST VS SUBSEQUENT SALVAGE THERAPY
EHA Learning Center, Franziska Severin, 215715
HEALTH-RELATED QUALITY OF LIFE AND RATES OF EMERGENCY ROOM VISITS AND HOSPITALIZATION IN PATIENTS WITH AL AMYLOIDOSIS: A PROSPECTIVE ANALYSIS
EHA Learning Center, Tiffany Quock, 215716
A HEALTH STATE UTILITY MODEL ESTIMATING THE IMPACT OF IVOSIDENIB ON QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Michael Storm, 215730
ASSESSMENT OF ADHERENCE IN HAEMOPHILIA PATIENTS - EVALUATION OF AN US INSTRUMENT AND DEVELOPMENT OF A NEW QUESTIONNAIRE FOR USE IN GERMANY
EHA Learning Center, Sylvia von Mackensen, 215731
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEDIATRIC PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY
EHA Learning Center, Paraskevi Klothaki, 215732
TICAGRELOR VERSUS PLACEBO FOR THE REDUCTION OF VASO-OCCLUSIVE CRISES IN PEDIATRIC SICKLE CELL DISEASE: DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER PHASE 3 STUDY (HESTIA3)
EHA Learning Center, Matthew Heeney, 215747
NOVEL TRIAL DESIGN TO EVALUATE ORAL VOXELOTOR FOR THE TREATMENT OF SICKLE CELL DISEASE: THE PHASE 3 HEMOGLOBIN OXYGEN AFFINITY MODULATION TO INHIBIT SICKLE HEMOGLOBIN POLYMERIZATION (HOPE) TRIAL
EHA Learning Center, Kenneth I. Ataga, 215748
OUTCOME OF PHILADELPHIA CHROMOSOME-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING TYROSINE KINASE INHIBITOR MAINTENANCE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Tuija Tapaninen, 215749
COMBINED EVALUATION OF DISEASE RISK INDEX AND ABCG2 EXPRESSION IDENTIFY AML PATIENTS AT A VERY HIGH RISK OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Daniela Damiani, 215763
AFTER ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION, A COMPOSITE SCORE BASED ON PLASMATIC LEVELS OF IL-2 RECEPTOR AND TIM-3, CAN PREDICT, AT DAY +18, TRM AND SEVERE A-GVHD
EHA Learning Center, Giuseppe MILONE, 215764
A NEW ULTRASONOGRAPHY-BASED SCORING SYSTEM IS EFFECTIVE DIAGNOSTIC TOOL FOR SINUSOIDAL OBSTRUCTION SYNDROME AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Mutsumi Nishida, 215765
LIFESTYLE BEHAVIOR AMONG LYMPHOMA SURVIVORS AFTER HIGH DOSE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hanne Bersvendsen, 215779
CTLA-4 GENE POLIMORPHISM INFLUENCE THE OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Petra Kovy, 215780
ELDERLY PATIENTS WITH MULTIPLE MYELOMA: LONG-TERM OUTCOME FOLLOWING INDUCTION WITH NOVEL DRUGS AND AUTOLOGOUS STEM CELL TRANSPLANT
EHA Learning Center, Swabirah Rassool, 215781
SERUM YKL-40 LEVELS IN PATIENTS WITH B-THALASSEMIA: RELATION TO VIRAL HEPATITIS, LIVER STIFFNESS AND HEPATIC IRON CONCENTRATION.
EHA Learning Center, Samah Mostafa, 215795
THE STRONG LINK BETWEEN PANCREAS AND HEART IN THALASSEMIA MAJOR.
EHA Learning Center, Alessia Pepe, 215796
THE INFLUENCE OF PGP AND PGR PEPTIDES ON ANTICOAGULANT CAPACITY AND ANTITHROMBOTIC POTENTIAL OF BLOOD IN HEMOSTATIC DYSFUNCTION OF AGING RATS
EHA Learning Center, Tamara Obergan, 215812
APTT-BASED CLOT WAVEFORM ANALYSIS IN VARIOUS INFECTIONS
EHA Learning Center, Cheng Kiat Lawrence Ng, 215813
AN ESSENTIAL ROLE OF LCK IN T-ALL CELL PROLIFERATION AND SURVIVAL
EHA Learning Center, Yuzhe Shi, 215892
METABOLOMIC ANALYSIS REVEALS CEREBROSPINAL FLUID CREATINE AND XANTHINE CONCENTRATIONS AS POTENTIAL BIOMARKERS FOR CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Antony Cousins, 215893
BONE MARROW FAILURE AND PREDISPOSITION TO LEUKEMIA IN GATA2 HAPLOINSUFFICIENT MICE
EHA Learning Center, Julia Weiss, 215908
WHOLE EXOME SEQUENCING OF SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Isabel Cuenca Navarro, 215909

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings